PT-141 (Bremelanotide): Research Guide & Mechanism
This comprehensive guide examines the latest research on pt-141 bremelanotide, covering mechanisms of action, published study data, research protocols, and safety considerations. As the field of peptide science continues to advance, understanding the evidence base for specific compounds and applications becomes increasingly important for researchers and investigators.
PT-141, also known as bremelanotide, represents a significant advance in melanocortin receptor research, being the first centrally-acting compound to receive FDA approval for hypoactive sexual desire disorder. This research guide covers the mechanism, clinical data, and safety profile of this unique peptide.
Researchers can access high-purity research compounds through Proxiva Labs, with all products verified via our third-party testing program.
Melanocortin Receptor Mechanism of Action
PT-141 is a cyclic heptapeptide that acts as a non-selective agonist at melanocortin receptors, with particular affinity for MC3R and MC4R subtypes in the central nervous system. Unlike phosphodiesterase inhibitors that act peripherally on vascular smooth muscle, PT-141 works through the hypothalamic melanocortin system to modulate sexual arousal and desire pathways.
- MC4R activation — Primary target for sexual function effects. MC4R is expressed in the paraventricular nucleus and medial preoptic area of the hypothalamus, regions critical for sexual behavior regulation
- MC3R involvement — Secondary receptor contributing to motivational and reward aspects of sexual behavior
- Dopaminergic downstream effects — MC4R activation stimulates dopamine release in the mesolimbic pathway, enhancing motivation and reward signaling
- Oxytocin pathway — Research suggests PT-141 may also stimulate oxytocin release from hypothalamic neurons, contributing to arousal and bonding behaviors
Clinical Trial Data
PT-141/bremelanotide underwent extensive clinical investigation, culminating in FDA approval in 2019 under the brand name Vyleesi.
RECONNECT Phase 3 Trials
Two pivotal phase 3 trials (RECONNECT-1 and RECONNECT-2) enrolled over 1,200 premenopausal women with hypoactive sexual desire disorder (HSDD). Results demonstrated statistically significant improvements in both desire and distress scores compared to placebo, with approximately 25% of treated patients achieving clinically meaningful improvement versus 17% for placebo.
- Satisfying sexual events increased by approximately 1.0 per month versus 0.7 for placebo
- Sexual desire scores improved significantly on validated FSFI and FSDS-DAO instruments
- Effects were observed within the first month of treatment
- Benefits were maintained over the 24-week study period
Male Sexual Dysfunction Studies
Earlier clinical studies also investigated PT-141 in male erectile dysfunction. In a phase 2 study, subcutaneous PT-141 induced erections in 8 of 10 men with erectile dysfunction, including several non-responders to sildenafil. This suggested the central mechanism could bypass peripheral vascular limitations.
Dosing Research and Administration
Published research and prescribing information provide clear dosing parameters for PT-141.
- Approved dose — 1.75 mg subcutaneous injection, administered at least 45 minutes before anticipated sexual activity
- Onset of action — Effects typically observed within 45-60 minutes of injection
- Duration — Effects may last up to 24 hours, with peak effect at approximately 2-4 hours
- Frequency limitation — Prescribing information recommends no more than one dose per 24 hours and no more than 8 doses per month
- Research doses — Clinical trials explored doses ranging from 0.75 mg to 4.0 mg, with 1.75 mg identified as the optimal balance of efficacy and tolerability
Safety Profile and Side Effects
The safety data from clinical trials provides a well-characterized side effect profile for PT-141.
- Nausea — The most common side effect, reported in approximately 40% of treated patients. Generally mild to moderate and self-limiting within hours
- Flushing — Reported in approximately 20% of patients, consistent with melanocortin receptor activation
- Headache — Occurring in approximately 11% of patients, typically mild
- Injection site reactions — Mild erythema or discomfort at injection sites reported in some patients
- Blood pressure — Transient increases in blood pressure (mean 2-3 mmHg systolic) observed post-dose, returning to baseline within 12 hours
- Hyperpigmentation — Focal skin darkening possible with repeated use due to MC1R activation
Notably, PT-141 does not carry the cardiovascular contraindications associated with phosphodiesterase inhibitors and has no known interaction with nitrates, making it a distinct pharmacological option in sexual function research.
Development History: From Melanotan to Bremelanotide
PT-141’s development history illustrates the serendipitous nature of drug discovery. It originated from melanotan II research, where sexual arousal was noted as an unexpected side effect of the tanning peptide. Researchers isolated and optimized the sexual function activity, creating a cyclic peptide that retained melanocortin receptor affinity while being optimized for sexual function endpoints. The initial intranasal formulation was abandoned due to blood pressure concerns, with the subcutaneous route ultimately proving safer and more predictable.
Key References
- Reynolds et al., 2021 — MOTS-C exercise
- Gomes et al., 2013 — NAD+ mitochondria
- Anisimov et al., 2003 — peptide longevity
Related Research Resources
Explore related topics in our research guide library:
- Semaglutide Weight Loss Results
- Future Weight Loss Peptides
- Peptides Vs Stem Cells
- Peptides For Back Pain Research
- Browse All Research Guides
Conclusion
PT-141 (bremelanotide) represents a first-in-class approach to modulating sexual function through the central melanocortin system, offering a mechanistically distinct alternative to peripheral vasodilators. The clinical validation of this pathway opens research opportunities in melanocortin biology, sexual neuroscience, and peptide pharmacology, with implications extending beyond sexual function into broader understanding of hypothalamic peptide signaling.
Researchers can explore our full catalog of research peptides and access the latest peptide research guides for ongoing updates in this rapidly evolving field.